68 related articles for article (PubMed ID: 24794108)
1. Synthesis of 5-methyl phenanthridium derivatives: a new class of human DOPA decarboxylase inhibitors.
Cheng P; Zhou J; Qing Z; Kang W; Liu S; Liu W; Xie H; Zeng J
Bioorg Med Chem Lett; 2014 Jun; 24(12):2712-6. PubMed ID: 24794108
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibitors of human DOPA decarboxylase extracted from Euonymus glabra Roxb.
Ren J; Zhang Y; Jin H; Yu J; Zhou Y; Wu F; Zhang W
ACS Chem Biol; 2014 Apr; 9(4):897-903. PubMed ID: 24471650
[TBL] [Abstract][Full Text] [Related]
3. Sanguinarine and chelerythrine as inhibitors of aromatic amino acid decarboxylase.
Drsata J; Ulrichová J; Walterová D
J Enzyme Inhib; 1996; 10(4):231-237. PubMed ID: 8872743
[TBL] [Abstract][Full Text] [Related]
4. Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
Maneckjee R; Baylin SB
Biochemistry; 1983 Dec; 22(26):6058-63. PubMed ID: 6661425
[TBL] [Abstract][Full Text] [Related]
5. Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Daidone F; Montioli R; Paiardini A; Cellini B; Macchiarulo A; Giardina G; Bossa F; Borri Voltattorni C
PLoS One; 2012; 7(2):e31610. PubMed ID: 22384042
[TBL] [Abstract][Full Text] [Related]
6. L-Dopa decarboxylase interaction with the major signaling regulator ΡΙ3Κ in tissues and cells of neural and peripheral origin.
Vassiliou AG; Siaterli MZ; Frakolaki E; Gkogkosi P; Paspaltsis I; Sklaviadis T; Vassilacopoulou D; Vassilaki N
Biochimie; 2019 May; 160():76-87. PubMed ID: 30796964
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antimalarial activity of new haemanthamine-type derivatives.
Cedrón JC; Gutiérrez D; Flores N; Ravelo ÁG; Estévez-Braun A
Bioorg Med Chem; 2012 Sep; 20(18):5464-72. PubMed ID: 22910226
[TBL] [Abstract][Full Text] [Related]
8. Reaction of dopa decarboxylase with L-aromatic amino acids under aerobic and anaerobic conditions.
Bertoldi M; Borri Voltattorni C
Biochem J; 2000 Dec; 352 Pt 2(Pt 2):533-8. PubMed ID: 11085948
[TBL] [Abstract][Full Text] [Related]
9. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of pig kidney L-aromatic amino acid decarboxylase by 2,3-methano-m-tyrosines.
Ahmad S; Phillips RS; Stammer CH
J Med Chem; 1992 Apr; 35(8):1410-7. PubMed ID: 1573634
[TBL] [Abstract][Full Text] [Related]
12. Influence of sanguinarine on the GABA synthesizing enzyme glutamate decarboxylase in vitro.
Netopilova M; Drsata J; Ulrichová J
Pharmazie; 1996 Aug; 51(8):589-91. PubMed ID: 8794470
[TBL] [Abstract][Full Text] [Related]
13. Structural perspective on the direct inhibition mechanism of EGCG on mammalian histidine decarboxylase and DOPA decarboxylase.
Ruiz-Pérez MV; Pino-Ángeles A; Medina MA; Sánchez-Jiménez F; Moya-García AA
J Chem Inf Model; 2012 Jan; 52(1):113-9. PubMed ID: 22107329
[TBL] [Abstract][Full Text] [Related]
14. Human L-Dopa decarboxylase interaction with annexin V and expression during apoptosis.
Chalatsa I; Arvanitis N; Arvanitis D; Tsakou AC; Kalantzis ED; Vassiliou AG; Sideris DC; Frakolaki E; Vassilaki N; Vassilacopoulou D
Biochimie; 2020 Oct; 177():78-86. PubMed ID: 32835737
[TBL] [Abstract][Full Text] [Related]
15. Detection, purification and identification of an endogenous inhibitor of L-Dopa decarboxylase activity from human placenta.
Vassiliou AG; Fragoulis EG; Vassilacopoulou D
Neurochem Res; 2009 Jun; 34(6):1089-100. PubMed ID: 19005753
[TBL] [Abstract][Full Text] [Related]
16. Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor.
Shemon AN; Sluyter R; Conigrave AD; Wiley JS
Br J Pharmacol; 2004 Jul; 142(6):1015-9. PubMed ID: 15210579
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of liver alanine aminotransferase activity by some benzophenanthridine alkaloids.
Walterová D; Ulrichová ; Preininger V; Simánek V; Lenfeld J; Lasovský J
J Med Chem; 1981 Sep; 24(9):1100-3. PubMed ID: 7288825
[TBL] [Abstract][Full Text] [Related]
18. Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes.
Kokkinou I; Nikolouzou E; Hatzimanolis A; Fragoulis EG; Vassilacopoulou D
Blood Cells Mol Dis; 2009; 42(1):92-8. PubMed ID: 19041269
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiplasmodial activity of lycorine derivatives.
Cedrón JC; Gutiérrez D; Flores N; Ravelo AG; Estévez-Braun A
Bioorg Med Chem; 2010 Jul; 18(13):4694-701. PubMed ID: 20627737
[TBL] [Abstract][Full Text] [Related]
20. Purification of an endogenous inhibitor of L-Dopa decarboxylase activity from human serum.
Vassiliou AG; Vassilacopoulou D; Fragoulis EG
Neurochem Res; 2005 May; 30(5):641-9. PubMed ID: 16176068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
